News

Sunstone Life Science Fund II portfolio company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the Company’s lead product candidate, VXM01, has received orphan designation from the European Commission and from the US Food and Drug Administration (FDA) for the treatment of glioma, a difficult-to-treat form of brain cancer. Orphan designation is designed to encourage the development of drugs to treat rare diseases and conditions and provides companies with certain incentives, including periods of market exclusivity upon approval, as well as user fee reductions or exemptions. The designation by the European Commission is for the treatment of glioma and by the US FDA for the treatment of malignant glioma.

Sunstone Life Science Fund II portfolio Company Anergis, a company developing proprietary ultra-fast allergy immunotherapy, has announced the top-line results from the ATIBAR trial, a Phase IIb field-based clinical trial with Anergis’ lead compound AllerT for patients with birch pollen allergy.

A total of 421 patients were randomized at 38 European trial centers in Denmark, Finland, Germany, Lithuania, Norway, Poland, Slovakia and Sweden between September 2016 and January 2017. The trial met its objective to provide conclusive results, with well-balanced treatment groups, very few dropouts, and narrow confidence intervals of the observed treatment effects. The pollen exposure was satisfactory as assessed by the data collected from the pollen traps located close to the trial centers.

Sunstone Life Science Fund III portfolio company, Rigontec GmbH and MSD today announced that MSD will acquire all outstanding shares in Rigontec. Under the terms of the agreement, MSD will make an upfront cash payment of EUR 115 million to Rigontec’s shareholders; based on the attainment of certain clinical, development, regulatory and commercial milestones, MSD may make additional contingent payments of up to EUR 349 million.

Rigontec is a pioneer in accessing the retinoic acid-inducible gene I (RIG-I) pathway, part of the innate immune system, as a novel and distinct approach in cancer immunotherapy to induce both immediate and long-term anti-tumor immunity. Rigontec’s lead candidate, RGT100, is currently in Phase I development evaluating treatment in patients with various tumors.

Rigontec was founded in 2014 as a spin-out of the University Bonn, Germany, and has to date raised close to EUR 30 million.

Sunstone Life Science Fund III portfolio Company Cantargia AB has announced that the European Patent Office (“EPO”) has granted the company’s patent application on the product candidate CAN04. CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval follows the intention to grant that EPO issued in April 2017.

The patent application with number 15714603.6 which was granted by the EPO, concerns the company’s product candidate CAN04. The patent protects CAN04 both as a substance as well for cancer treatment. The patent gives protection in Europe until 2035. In addition to the patent granted in Europe, a notice of allowance was obtained in the USA in June 2017. The application has also been submitted in a large number of additional territories such as Japan and China.

One of the highlights of the Emerging Technology Showcase Area at the European Society of Cardiology Congress in Barcelona, will be Swedish/Danish Acarix AB’s (publ) (“Acarix”) CADScor®System, an advanced, easy to use, frontline test to rule out Coronary Artery Disease (CAD) with high accuracy.  Initial study results released earlier this year show that the Danish Design Award winning CADScor®System non-invasively rules out CAD with 97% negative predictive value. Following this, the CADScor®System has been commercially launched in the Nordics and Germany to both private and public cardiology centers.

In addition to seeing demonstrations of the CADScor®System on booth F140 in the Emerging Technology Showcase Area, delegates will also be able to learn about study results from Principal Investigator Morten Böttcher, MD PhD FESC and Simon Winther, MD PhD, Department of Cardiology, Herning Hospital, Denmark.